These experiments suggested that PRMT5 may be a therapeutic target in CRC treatment, as tadalafil is already been approved by FDA for erectile dysfunction and pulmonary arterial hypertension (PAH) treatment [24]. This evidence concerns the gene PRMT5 and pulmonary arterial hypertension.